- Home
- BLBX vs BTAI Comparison
BLBX vs BTAI Comparison
Compare BLBX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLBX
- BTAI
- Stock Information
- Founded
- BLBX 2014
- BTAI 2017
- Country
- BLBX United States
- BTAI United States
- Employees
- BLBX N/A
- BTAI N/A
- Industry
- BLBX EDP Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- BLBX Technology
- BTAI Health Care
- Exchange
- BLBX Nasdaq
- BTAI Nasdaq
- Market Cap
- BLBX 10.6M
- BTAI 8.4M
- IPO Year
- BLBX N/A
- BTAI 2018
- Fundamental
- Price
- BLBX $3.88
- BTAI $1.37
- Analyst Decision
- BLBX
- BTAI Buy
- Analyst Count
- BLBX 0
- BTAI 5
- Target Price
- BLBX N/A
- BTAI $42.60
- AVG Volume (30 Days)
- BLBX 36.1K
- BTAI 418.0K
- Earning Date
- BLBX 05-15-2025
- BTAI 05-12-2025
- Dividend Yield
- BLBX N/A
- BTAI N/A
- EPS Growth
- BLBX N/A
- BTAI N/A
- EPS
- BLBX N/A
- BTAI N/A
- Revenue
- BLBX $2,504,604.00
- BTAI $1,852,000.00
- Revenue This Year
- BLBX N/A
- BTAI $27.23
- Revenue Next Year
- BLBX N/A
- BTAI $217.72
- P/E Ratio
- BLBX N/A
- BTAI N/A
- Revenue Growth
- BLBX N/A
- BTAI 5.47
- 52 Week Low
- BLBX $1.51
- BTAI $1.17
- 52 Week High
- BLBX $6.00
- BTAI $29.28
- Technical
- Relative Strength Index (RSI)
- BLBX 61.25
- BTAI 42.33
- Support Level
- BLBX $3.73
- BTAI $1.17
- Resistance Level
- BLBX $4.07
- BTAI $1.48
- Average True Range (ATR)
- BLBX 0.21
- BTAI 0.11
- MACD
- BLBX 0.03
- BTAI 0.01
- Stochastic Oscillator
- BLBX 74.32
- BTAI 58.82
About BLBX Blackboxstocks Inc.
Blackboxstocks Inc is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Its web-based software (the Blackbox System) employs predictive technology enhanced by artificial intelligence to find volatility and unusual market activity that may result in a rapid change in the price of a stock or option. It provides users with a fully interactive social media platform that is integrated into its dashboard, enabling users to exchange information and ideas quickly and efficiently through a common network. The company introduced a live audio/video feature that allows members to broadcast on their channels to share trading strategies and market insight within the Blackbox community.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.